Anfeng Geng - Cabio Biotech Deputy Manager
| 688089 Stock | 28.83 4.49 18.45% |
Executive
Anfeng Geng is Deputy Manager of Cabio Biotech Wuhan
| Age | 49 |
| Address | No. 999 high-tech Avenue, Wuhan, China, 430073 |
| Phone | 86 27 6784 5351 |
| Web | https://www.cabio.cn |
Cabio Biotech Management Efficiency
The company has return on total asset (ROA) of 0.0383 % which means that it generated a profit of $0.0383 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0814 %, meaning that it generated $0.0814 on every $100 dollars invested by stockholders. Cabio Biotech's management efficiency ratios could be used to measure how well Cabio Biotech manages its routine affairs as well as how well it operates its assets and liabilities. At present, Cabio Biotech's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 61.9 M, whereas Total Assets are forecasted to decline to about 1.2 B.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Ke Wen | Impulse Qingdao Health | 51 | |
| Chunhon Liang | Impulse Qingdao Health | 55 | |
| Xianfeng Gu | Guangdong Silvere Sci | 55 | |
| Cuiliang Xue | Tibet Huayu Mining | 46 | |
| Rui Zhang | Impulse Qingdao Health | 47 | |
| Jiale He | Anhui Huaren Health | 48 | |
| Zhigang Zhao | Uroica Mining Safety | 54 | |
| Lu Chen | Huaxia Eye Hospital | 47 | |
| Yaolin Lin | Mingchen Health Co | N/A | |
| Yan Sun | Tibet Huayu Mining | 46 | |
| Wenzheng Xie | Tibet Huayu Mining | 66 | |
| Liang Liu | Tibet Huayu Mining | 41 | |
| Gui Zheng | Guangdong Silvere Sci | 47 | |
| Yan Wang | Tibet Huayu Mining | 60 | |
| Jian Xing | Tibet Huayu Mining | 55 | |
| Shilai Jiang | Tibet Huayu Mining | 58 | |
| Nai Cao | Huaxia Eye Hospital | 50 | |
| Zhixia Liu | Tibet Huayu Mining | N/A | |
| Jianyong Bi | Impulse Qingdao Health | 49 | |
| Hongwei Cao | Uroica Mining Safety | 58 | |
| Xi Qin | Impulse Qingdao Health | 55 | |
Management Performance
| Return On Equity | 0.0814 | ||||
| Return On Asset | 0.0383 |
Cabio Biotech Wuhan Leadership Team
Elected by the shareholders, the Cabio Biotech's board of directors comprises two types of representatives: Cabio Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cabio. The board's role is to monitor Cabio Biotech's management team and ensure that shareholders' interests are well served. Cabio Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cabio Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anfeng Geng, Deputy Manager | ||
| Tao Ma, Deputy Manager | ||
| Dewei Yi, Chairman GM | ||
| Zhiming Wang, Deputy Manager | ||
| Hao Xiong, Accounting Supervisor | ||
| Min Xiao, Chief Director | ||
| Huarong Yi, Deputy Directors | ||
| Xiangyu Li, Deputy Manager | ||
| Huabiao Wang, Financial Director |
Cabio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cabio Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0814 | ||||
| Return On Asset | 0.0383 | ||||
| Profit Margin | 0.22 % | ||||
| Operating Margin | 0.33 % | ||||
| Current Valuation | 4.71 B | ||||
| Shares Outstanding | 168.31 M | ||||
| Shares Owned By Insiders | 50.75 % | ||||
| Shares Owned By Institutions | 4.86 % | ||||
| Price To Book | 3.18 X | ||||
| Price To Sales | 8.74 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Cabio Stock
Cabio Biotech financial ratios help investors to determine whether Cabio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cabio with respect to the benefits of owning Cabio Biotech security.